Preeclampsia (PE) affects 1 in 20 pregnancies and remains a leading cause of maternal and fetal morbidity and mortality worldwide. PE is characterised by hypertension after 20 weeks gestation with proteinuria, uteroplacental dysfunction and/or maternal organ dysfunction. A characteristic endpoint of PE is widespread maternal vascular dysfunction caused by placental-derived factors and oxidative stress. Novel therapeutics that can target this underlying vascular dysfunction are extremely exciting as future adjuvant therapies. This talk will detail an advanced model for replicating the vascular dysfunction of preeclampsia ‘in a dish’ and using the leading technique of wire myography to assess the potential of therapies to improve vascular dysfunction.